ERBB2 and gastroesophageal junction adenocarcinoma: The TOGA trial established the addition of the HER-directed antibody trastuzumab to chemotherapy with fluoropyrimidine plus cisplatin-based systemic therapy in patients with HER2-positive status in the 1st line palliative treatment of esophagogastric adenocarcinoma [48].